iBio, Inc. (NASDAQ:IBIO) Stock Has Average Price Target of $6.00 According to Analysts

Key Points

• Analysts have a consensus “Buy” rating on iBio, with five buy, two strong-buy and one sell recommendation. The average 12-month price target is $6.00, including recent targets of $5.00 from Chardan Capital and $7.00 from HC Wainwright.
• iBio shares opened at $0.78, well below their one-year high of $3.82, with a market capitalization of approximately $50.4 million. The company’s latest quarterly loss of $0.04 per share was narrower than analysts’ expected loss of $0.07.
• Several institutional investors increased their iBio holdings, though institutional ownership remains relatively low at 7.9%. The biotechnology company is developing next-generation antibody therapeutics using artificial intelligence, machine learning and computational biology.

Shares of iBio, Inc. (NASDAQ:IBIO - Get Free Report) have earned a consensus rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.00.

A number of brokerages have recently weighed in on IBIO. Weiss Ratings restated a "sell (d-)" rating on shares of iBio in a research note on Monday, September 21st. Chardan Capital restated a "buy" rating and set a $5.00 price target on shares of iBio in a report on Thursday, July 2nd. Wall Street Zen downgraded shares of iBio from a "hold" rating to a "sell" rating in a research note on Sunday, September 13th. Finally, HC Wainwright started coverage on iBio in a research note on Thursday, September 17th. They set a "buy" rating and a $7.00 price target on the stock.

iBio Price Performance

Shares of IBIO opened at $0.78 on Friday. iBio has a one year low of $0.73 and a one year high of $3.82. The company has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.50. The stock has a market cap of $50.42 million, a price-to-earnings ratio of -2.31 and a beta of 1.26.

iBio (NASDAQ:IBIO - Get Free Report) last issued its quarterly earnings results on Friday, August 28th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. Analysts anticipate that iBio will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On iBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Headlands Technologies LLC raised its stake in shares of iBio by 333.0% in the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock valued at $83,000 after buying an additional 36,463 shares in the last quarter. Bank of America Corp DE increased its stake in iBio by 150.8% in the first quarter. Bank of America Corp DE now owns 290,413 shares of the company's stock valued at $552,000 after acquiring an additional 174,620 shares during the period. Noesis Capital Mangement Corp increased its stake in iBio by 38.9% in the first quarter. Noesis Capital Mangement Corp now owns 311,500 shares of the company's stock valued at $592,000 after acquiring an additional 87,300 shares during the period. Walleye Capital LLC raised its position in iBio by 95.9% in the first quarter. Walleye Capital LLC now owns 388,554 shares of the company's stock worth $738,000 after purchasing an additional 190,179 shares in the last quarter. Finally, ADAR1 Capital Management LLC raised its position in iBio by 15.9% in the first quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock worth $893,000 after purchasing an additional 64,347 shares in the last quarter. Institutional investors own 7.90% of the company's stock.

iBio Company Profile

iBio, Inc is a biotechnology company focused on the discovery and development of next-generation biotherapeutics. The company uses artificial intelligence, machine learning and computational biology to identify promising antibody candidates, characterize their target epitopes and support the design of potentially differentiated medicines.

iBio's technology platform is designed to help address challenges in antibody discovery and development, including selecting suitable biological targets and engineering antibodies with desired characteristics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.